TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer

Part of paid clinical trials in Bridgewater, New Jersey.

Sponsor
Sanofi
Study ID
NCT00399750
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • oxaliplatin — DRUG
  • fluoropyrimidine — DRUG
  • bevacizumab — DRUG

Study Details

A randomized, controlled, open-label multicenter trial to assess the safety and efficacy of 3 oxaliplatin-fluoropyrimidine containing regimens (mFOLFOX6; bFOL; XELOX) + Bevacizumab (TREE1 and TREE2) as first line therapy of advanced metastatic colorectal cancer.

Key Dates

First listed
Nov 15, 2006
Start date
Nov 30, 2002
Status verified
Oct 2009
Completion
Jun 30, 2005

Study Design

Enrollment
373 participants
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2)

Locations (1)

FacilityCityStateZIPSite coordinators
Sanofi-AventisBridgewaterNew Jersey08807-

Find similar trials in Bridgewater, NJ

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
Sanofi-Aventis· Bridgewater, NJ

Related Studies